SG10201407329RA - Modified vasoactive intestinal peptides - Google Patents

Modified vasoactive intestinal peptides

Info

Publication number
SG10201407329RA
SG10201407329RA SG10201407329RA SG10201407329RA SG10201407329RA SG 10201407329R A SG10201407329R A SG 10201407329RA SG 10201407329R A SG10201407329R A SG 10201407329RA SG 10201407329R A SG10201407329R A SG 10201407329RA SG 10201407329R A SG10201407329R A SG 10201407329RA
Authority
SG
Singapore
Prior art keywords
vasoactive intestinal
modified
intestinal peptides
vip
modified vasoactive
Prior art date
Application number
SG10201407329RA
Other languages
English (en)
Inventor
Homayoun Sadeghi
Andrew Turner
Suzanne Dagher
Original Assignee
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals Inc filed Critical Phasebio Pharmaceuticals Inc
Publication of SG10201407329RA publication Critical patent/SG10201407329RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG10201407329RA 2009-08-14 2010-08-16 Modified vasoactive intestinal peptides SG10201407329RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23415109P 2009-08-14 2009-08-14

Publications (1)

Publication Number Publication Date
SG10201407329RA true SG10201407329RA (en) 2015-01-29

Family

ID=43586545

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201407329RA SG10201407329RA (en) 2009-08-14 2010-08-16 Modified vasoactive intestinal peptides

Country Status (19)

Country Link
US (5) US9029505B2 (cg-RX-API-DMAC7.html)
EP (2) EP3311828B1 (cg-RX-API-DMAC7.html)
JP (3) JP5801807B2 (cg-RX-API-DMAC7.html)
KR (2) KR101943420B1 (cg-RX-API-DMAC7.html)
CN (1) CN102596217B (cg-RX-API-DMAC7.html)
AU (3) AU2010282250B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012003327A2 (cg-RX-API-DMAC7.html)
CA (1) CA2804755C (cg-RX-API-DMAC7.html)
DK (2) DK2464370T3 (cg-RX-API-DMAC7.html)
ES (2) ES2870914T3 (cg-RX-API-DMAC7.html)
HU (2) HUE032703T2 (cg-RX-API-DMAC7.html)
IL (1) IL218116A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN02120A (cg-RX-API-DMAC7.html)
MX (2) MX366935B (cg-RX-API-DMAC7.html)
PL (2) PL2464370T3 (cg-RX-API-DMAC7.html)
PT (2) PT3311828T (cg-RX-API-DMAC7.html)
RU (1) RU2589255C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201407329RA (cg-RX-API-DMAC7.html)
WO (1) WO2011020091A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
MX366935B (es) 2009-08-14 2019-07-31 Phasebio Pharmaceuticals Inc Peptidos intestinales vasoactivos modificados.
EP2717902B1 (en) * 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
JP6169079B2 (ja) * 2011-08-24 2017-07-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 徐放のための活性剤の製剤
RU2014126244A (ru) * 2011-11-28 2016-01-27 Фэйзбио Фармасьютикалз, Инк. Лекарственные средства, содержащие аминокислотные последовательности инсулина
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
JP7075757B2 (ja) 2014-11-21 2022-05-26 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 制御放出および持続的放出のためのｅｌｐ融合タンパク質
CN105753990B (zh) * 2014-12-19 2018-07-03 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
CN107427556B (zh) * 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
WO2017152399A1 (zh) * 2016-03-09 2017-09-14 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
EP4043010A1 (en) 2016-05-06 2022-08-17 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
CN107056922A (zh) * 2016-12-24 2017-08-18 山东明鑫集团有限公司 一种具有降血糖作用的pacap多肽类似物的制备方法
US11786580B2 (en) * 2018-04-23 2023-10-17 Emory University VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated disease
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
KR102719035B1 (ko) * 2020-04-20 2024-10-18 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도
US20230173030A1 (en) * 2020-05-05 2023-06-08 Phasebio Pharmaceuticals, Inc. Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
EP4326310A1 (en) 2021-04-20 2024-02-28 AdVita Lifescience AG Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome
DE102024001175A1 (de) 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.
CN119390812B (zh) * 2024-11-08 2025-07-29 三亚市私域大健康医院有限公司 一种治疗勃起功能障碍的干细胞外泌体组合物及其用途

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132746A (en) * 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
US4187852A (en) 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4500700A (en) * 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4474851A (en) * 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4589882A (en) * 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4734400A (en) 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4870055A (en) * 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US4783523A (en) * 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US6184348B1 (en) * 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US5770697A (en) * 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5830713A (en) * 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5773249A (en) * 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4939224A (en) 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5141924A (en) 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
US5234907A (en) * 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
DE69105323T2 (de) 1990-03-27 1995-06-01 Bioelastics Res Ltd Bioelastomeres Arzneimittelabgabesystem.
DK0463450T3 (da) * 1990-06-26 1994-06-27 Sanwa Kagaku Kenkyusho Co Vasoaktive intestinale polypeptid-analoger og udnyttelsen heraf
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US5235041A (en) * 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) * 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
US5681816A (en) * 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) * 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
JPH10502333A (ja) * 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド
US5527610A (en) * 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US5972406A (en) * 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US5854387A (en) 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) * 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
AU716154B2 (en) 1995-09-01 2000-02-17 University Of Washington Interactive molecular conjugates
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
AU722895B2 (en) 1996-02-09 2000-08-10 F. Hoffmann-La Roche Ag Synthesis of VIP analog
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5816259A (en) * 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU2798599A (en) 1998-02-27 1999-09-15 Bioelastics Research Ltd. Injectable implants for tissue augmentation and restoration
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020151458A1 (en) * 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
ES2138561B1 (es) * 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6541033B1 (en) * 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
AU3867400A (en) * 1999-03-19 2000-10-09 Duke University Methods of using bioelastomers
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
AU2249701A (en) * 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6593394B1 (en) * 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2001060863A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
WO2001060862A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
ES2275685T3 (es) * 2000-06-16 2007-06-16 Eli Lilly And Company Analogos del peptido similar a glucagon 1.
AU2001273632A1 (en) 2000-06-23 2002-01-08 Drexel University Polymeric, fiber matrix delivery systems for bioactive compounds
EP1337557A2 (en) * 2000-11-28 2003-08-27 Mondobiotech SA Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
DK1355942T3 (da) * 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
MXPA03005135A (es) * 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
AU2002322403A1 (en) * 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
KR20040065212A (ko) 2001-11-06 2004-07-21 센주 세이야꾸 가부시키가이샤 건조안 및 건조안과 연관된 질환의 치료제
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
CN101015679A (zh) 2002-06-10 2007-08-15 蒙杜生物科技安斯塔特实验室 具有血管活性肠肽的生物学活性的化合物在治疗结节病中的用途
ATE521624T1 (de) * 2002-11-27 2011-09-15 Ils Inc Peptide und medizinische zusammensetzungen mit denselben
WO2004104020A2 (en) * 2003-05-14 2004-12-02 Dow Corning Corporation Repeat sequence protein polymer active agent conjugates, methods and uses
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
CN1917898B (zh) 2003-07-14 2011-08-17 盟多生化股份公司 用于治疗间质肺部感染的血管活性肠肽的生物活性物质
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US20050203009A1 (en) * 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
WO2005097158A1 (en) * 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
CA2567635A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
DK1768689T3 (en) * 2004-06-11 2014-12-01 Vectus Biosystems Ltd Compositions and methods for treating cardiovascular disease
CN101001639A (zh) * 2004-06-12 2007-07-18 拜尔药品公司 血管活性肠肽(vip)/垂体腺苷酸环化酶活化肽(pacap)受体2(vpac2)激动剂的聚乙二醇化和使用方法
WO2006023358A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
CN101056647A (zh) * 2004-10-08 2007-10-17 福布斯梅迪泰克（研究）公司 肠血管活性多肽药物
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
WO2007002362A2 (en) 2005-06-24 2007-01-04 Duke University A direct drug delivery system based on thermally responsive biopolymers
AU2006306236B2 (en) * 2005-10-26 2011-12-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
ATE458000T1 (de) * 2005-11-18 2010-03-15 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
CA2952475C (en) * 2005-12-09 2022-08-09 Vectus Biosystems Limited Vip fragment for the treatment of myocardial fibrosis
US8178495B2 (en) * 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
US8334257B2 (en) * 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8367626B2 (en) * 2006-05-12 2013-02-05 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
US20110039776A1 (en) * 2006-09-06 2011-02-17 Ashutosh Chilkoti Fusion peptide therapeutic compositions
CA2687602C (en) 2007-05-21 2014-07-15 Res International Sarl Peptides with improved properties having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases
EP2185701A4 (en) * 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
CN102227430A (zh) 2008-10-23 2011-10-26 沃泰克斯药物股份有限公司 囊性纤维化跨膜传导调节因子的调节剂
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
MX366935B (es) 2009-08-14 2019-07-31 Phasebio Pharmaceuticals Inc Peptidos intestinales vasoactivos modificados.
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis

Also Published As

Publication number Publication date
CA2804755A1 (en) 2011-02-17
MX2012001979A (es) 2012-06-25
PL2464370T3 (pl) 2017-08-31
HUE032703T2 (en) 2017-10-30
IN2012DN02120A (cg-RX-API-DMAC7.html) 2015-08-21
AU2017279636A1 (en) 2018-01-18
CN102596217A (zh) 2012-07-18
US9029505B2 (en) 2015-05-12
WO2011020091A1 (en) 2011-02-17
US20240091313A1 (en) 2024-03-21
AU2016200897A1 (en) 2016-03-03
JP2017066157A (ja) 2017-04-06
MX339031B (es) 2016-05-05
EP2464370A4 (en) 2013-03-27
PT3311828T (pt) 2021-05-05
EP2464370A1 (en) 2012-06-20
IL218116A0 (en) 2012-04-30
RU2589255C2 (ru) 2016-07-10
PT2464370T (pt) 2017-05-17
US20180008677A1 (en) 2018-01-11
JP6229038B2 (ja) 2017-11-08
AU2016200897B2 (en) 2017-10-12
US9700598B2 (en) 2017-07-11
ES2624478T3 (es) 2017-07-14
DK3311828T3 (da) 2021-06-28
US20160220642A1 (en) 2016-08-04
EP2464370B1 (en) 2017-03-29
JP2013501818A (ja) 2013-01-17
JP6069441B2 (ja) 2017-02-01
CA2804755C (en) 2018-06-05
DK2464370T3 (en) 2017-05-15
CN102596217B (zh) 2014-07-02
KR101943420B1 (ko) 2019-04-17
US20250325635A1 (en) 2025-10-23
PL3311828T3 (pl) 2021-11-22
KR20170085611A (ko) 2017-07-24
AU2010282250A1 (en) 2012-04-05
ES2870914T3 (es) 2021-10-28
KR101887009B1 (ko) 2018-08-09
US20110178017A1 (en) 2011-07-21
EP3311828A1 (en) 2018-04-25
BR112012003327A2 (pt) 2017-06-06
AU2017279636B2 (en) 2019-09-12
HUE054744T2 (hu) 2021-12-28
KR20120062777A (ko) 2012-06-14
EP3311828B1 (en) 2021-04-07
JP2016000751A (ja) 2016-01-07
JP5801807B2 (ja) 2015-10-28
AU2010282250B2 (en) 2015-11-12
MX366935B (es) 2019-07-31
RU2012109553A (ru) 2013-09-20
IL218116A (en) 2017-06-29

Similar Documents

Publication Publication Date Title
SG10201407329RA (en) Modified vasoactive intestinal peptides
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
TW200716646A (en) (S)-N-methylnaltrexone
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2010004374A (es) Armazones proteinicos.
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
MX2009005466A (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
TN2010000213A1 (en) Wise binding antibodies and epitopes
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
WO2008021156A3 (en) Antibodies to il-17a
MY156315A (en) Anti-vegf antibodies
MY159135A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY158992A (en) Forms of rifaximin and uses thereof
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
NZ595361A (en) Chimeric factor h binding proteins (fhbp) and methods of use
MX2012003951A (es) Preparacion farmceutica que comprende hcg recombinante.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX336384B (es) Composiciones que comprenden fragmentos de péptido intestinal vasoactivoa para uso en el tratameinto terapéutico de fibrosis renal.
MX2012006980A (es) Polipeptidos de somatotropina porcina modificados y sus usos.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
SG10201805749QA (en) Substantially animal protein-free recombinant furin and methods for producing same